| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| ln Vivo |
Treatment for NASH (nonalcoholic steatohepatitis) with pemvidutide (subcutaneous injection; 5 or 10 nmol/kg; once daily; 12 w) improves NASH outcomes in vivo[1].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: C57BL6/J mice (with biopsy-confirmed NAS score after 29 weeks on a HFFC diet)[1]
Doses: 5 or 10 nmol/kg Route of Administration: subcutaneous (sc) injection; 5 or 10 nmol/kg; one time/day; 12 weeks Experimental Results: Lowered hepatic lipids, liver weight, biomarkers of liver injury (plasma ALT and AST ), the inflammation marker galactin-3, the fibrosis marker Col1a1, and the NAS score. |
| References |
[1]. Yabut JM, et al. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease. Endocr Rev. 2022 Jul 30:bnac018.
|
| Molecular Formula |
C178H270N38O53
|
|---|---|
| Molecular Weight |
3790.27124547958
|
| CAS # |
2538014-94-5
|
| Related CAS # |
Pemvidutide TFA
|
| Sequence |
His-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu--{Lys(N6-(1-O-(17-Carboxyheptadecyl)-D-Glucopyranuronoyl))}-Ala-Ala-Lys-Glu-Phe-Ile-Gln-Trp-Leu-Leu-Gln-Thr-NH2 (Lactam bridge: Glu-16;Lys-20)H-{Aib}-QGTFTSDYSKYLDE-{Lys(N6-(1-O-(17-Carboxyheptadecyl)-D-Glucopyranuronoyl))}-AAKEFIQWLLQT-NH2 (Lactam bridge: Glu-16;Lys-20)
|
| SequenceShortening |
H-{Aib}-QGTFTSDYSKYLDE-{Lys(N6-(1-O-(17-Carboxyheptadecyl)-D-Glucopyranuronoyl))}-AAKEFIQWLLQT-NH2 (Lactam bridge: Glu-16;Lys-20)
|
| Appearance |
White to off-white solid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 100 mg/mL (~25.8 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (0.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (0.65 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Suspended solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: 2.5 mg/mL (0.65 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Suspended solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.2638 mL | 1.3192 mL | 2.6383 mL | |
| 5 mM | 0.0528 mL | 0.2638 mL | 0.5277 mL | |
| 10 mM | 0.0264 mL | 0.1319 mL | 0.2638 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
